New at #HiD25: Kausik Ray FMedSci, director of the Imperial Centre for Cardiovascular Disease Prevention, sat down with us to discuss his presentation on CETP inhibitors and how they may be used to predict cardiovascular events.

Watch the full interview: www.hcplive.com/view...

New at #HiD25: We sat down with Matthew Budoff, MD, to discuss his recent study on predicting cardiovascular disease in patients without traditional warning signs via serum lipoproteins.

Watch the full interview: www.hcplive.com/view...

New at #HiD25: Kausik Ray FMedSci, director of the Imperial Centre for Cardiovascular Disease Prevention, sat down with us to discuss his presentation on the future of dual agonists in treating obesity and its many complications.

Watch the full interview: www.hcplive.com/view/dual-ag...

New at #HiD25: Martha Gulati, MD, sat down with us to discuss her presentation on incretins, GLP-1 receptor agonists, and the future of obesity treatment and prevention.

Watch the full interview: www.hcplive.com/view/the-fut...

New at #HiD25: We sat down with Matthew Weir, MD, professor and director of the division of nephrology at the University of Maryland School of Medicine, to discuss his presentation on whether ACE/ARB inhibitors still have a place in modern treatment.

Watch now: www.hcplive.com/view...

New in #HiD25: A pooled analysis of the BROOKLYN and BROADWAY trials proves that obicetrapib reduces HbA1c and new-onset diabetes risk in patients with ASCVD.

Read more: www.hcplive.com/view...

New at #HiD25: cardiovascular risk may actually be higher in patients with lower BMIs, according to new research. This is indicative of the "obesity paradox", when individuals with higher BMI experience less negative outcomes.

Read more: www.hcplive.com/view...

New from #HiD25: We met with Jennifer Green, MD, Duke University School of Medicine, to discuss her presentation on the future of incretin therapy and how it can be applied to diseases beyond obesity and diabetes.

Watch the full interview: www.hcplive.com/view/the-fut...

New at #HiD25: We sat down with Jose Lopez, MD, a cardiovascular disease fellow at the University of Miami Miller School of Medicine/JFK Medical Center, to discuss racial and ethnic differences in risk of more severe diabetic cardiomyopathy.

Watch the full interview: www.hcplive.com/view/recogni...

New at #HiD25: we sat down with Robert Califf, MD, former commissioner of the FDA, to discuss his presentation on the shortcomings of technological advancements and the industry's inability to collate these massive amounts of data.

Watch the full interview: www.hcplive.com/view/confron...

New at #HiD25: @erinmichos.bsky.social, director of women's cardiovascular health at Johns Hopkins University, met with us to discuss her presentation on postmenopausal hormone imbalance, obesity, and cardiovascular disease risk in women.

Watch the interview here: www.hcplive.com/view/post-me...

Another recent study at the 9th Annual Heart in Diabetes Conference has indicated the surprising cardiopulmonary benefits of GLP-1 receptor agonists in patients with type 2 diabetes and obstructive sleep apnea.

Read now: www.hcplive.com/view...

#HiD25

Ontdekte deze week tijdens #HID25 een leverancier van ‘print-op-snee’ machine - zie het nu in Zwitserse boekwinkel liggen

Sympathiek: een ‘straatbieb’ op station Basel, waar reizigers gratis boeken kunnen ruilen. Onderweg van #HID25 Luzern naar Alkmaar.

www.printing-connect.online/blog/connex-...
#hid25